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Intravascular Ultrasound Tissue Characterization
Messages From the Heart*
Sanjay Kaul, MD,†‡§ George A. Diamond, MD‡§
Los Angeles, CaliforniaWhy are there so many
Songs about rainbows
And what’s on the other side
Rainbows are visions
They’re only illusions
And rainbows have nothing to hide
—Kermit the Frog
The Rainbow Connection (1)
Cardiac biomarkers of necrosis have been described
as providing clinicians with important “messages”
from the heart (2). They play an integral role in the
clinical diagnosis of myocardial infarction (MI).
In addition to providing diagnostic information,
cardiac biomarkers also offer clinicians a valuable
tool for prognostication and therapeutic decision
making. The European Society of Cardiology/
American College of Cardiology/American Heart
Association/World Heart Federation task force re-
cently codified myocardial infarction into 5 types
See page 458
(3). Of particular interest, especially to the inter-
ventional cardiologist, is the type 4a, MI associated
with percutaneous coronary intervention (PCI).
The universal definition of MI arbitrarily defines a
post-PCI MI, among patients with normal pre-
procedural values, as an increase in biomarker value
that is 3 the upper limit of normal (99th
percentile). Cardiac troponins are the preferred
biomarker of choice in defining post-PCI MI (3).
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the †Division of Cardiology, Cedars-Sinai Heart Institute,
‡Cedars-Sinai Medical Center, and the §David Geffen School of Med-
icine, University of California, Los Angeles, California.A large number of studies have shown that
mild-to-moderate elevations of cardiac biomarkers
are detected in 10% to 43% of cases after PCI (2–4).
Elevations of cardiac troponins occur more fre-
quently than elevations of creatine kinase (CK)-MB
after elective PCI. Although post-procedural car-
diac troponin level elevation is associated with
abnormal tissue-level perfusion (5) and irreversible
myocardial injury (6), the clinical and prognostic
impact of post-procedural cardiac biomarker release
is not unambiguously established. Studies have
yielded inconsistent results, with some reporting
that an elevated troponin level is, and others that it
is not, an independent predictor of survival (2–4).
Interpretations have ranged from a direct cause-
and-effect association between any level of bio-
marker elevation and subsequent mortality to the
biomarker elevations representing a marker of high
risk such as disease severity, plaque characteristic, or
inflammatory status. More recently, studies have
indicated that pre-procedural rather than post-
procedural cardiac troponin level is a powerful
independent predictor of prognosis (4).
An important implication of the argument that
there is a relationship between the cardiac bio-
marker released and long-term risk of adverse
cardiac outcomes is that prevention of periproce-
dural MI, either through a priori identification of
the plaques that are associated with these events
and/or by the use of drugs and devices that reduce
periprocedural MI, would be desirable. In this issue
of iJACC, Hong et al. (7) study the relationship of
pre-PCI measures of plaque composition and post-
PCI cardiac troponin I (cTnI) elevation in 80
selected patients undergoing nonurgent PCI at a
single center over a 1-year period from 2005 to
2006. The plaque composition was assessed by
virtual histology (VH)-intravascular ultrasound
(IVUS) (Volcano Therapeutics, Inc., Rancho Cor-
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470ova, California), in which spectral analysis of
adiofrequency ultrasound backscatter signals from
he IVUS images are displayed in a rainbow of
olors to define fibrous (green), fibro-fatty (yellow-
reen), dense calcific (white), and necrotic core
red) areas within the plaque. The principal finding
as that the plaque necrotic area was an indepen-
ent predictor of post-PCI TnI elevation. The
nvestigators conclude that “VH-IVUS may play an
mportant role detecting which lesions are high
isks for myocardial necrosis after PCI.”
Identification of plaque at high risk for distal
mbolization or myonecrosis remains a challenge
uring coronary interventions. Tissue characteriza-
ion of plaque components by VH-IVUS might
rovide useful information in this setting, thereby
ffering an opportunity for validation of the clinical
tility of this technology. Accordingly, several stud-
es have focused on the identification of markers of
istal embolization in patients with acute MI,
nstable angina, or stable angina using the VH-
VUS technology (8–11). In patients with ST-
egment elevation myocardial infarction undergoing
rimary stenting, a positive correlation was found
etween plaque necrotic core volume and ST-
egment re-elevation (surrogate marker for distal
mbolization) in the study by Kawaguchi et al. (8).
owever, in another study by Nakamura et al. (9),
he appearance of no-reflow was not correlated to
he volume of necrotic core. Kawamoto et al. (10)
nvestigated the relationship between VH findings
nd high-intensity transient signals by intracoro-
ary Doppler (surrogate for small particle emboli-
ation) and observed that only necrotic core area
merged as an independent predictor of Doppler-
etected distal embolization. Using integrated
ackscatter-IVUS technology, Uetani et al. (11)
ecently showed in relatively stable patients under-
oing elective coronary stenting that myonecrosis
ssessed by CK-MB and troponin-T in single blood
amples at 18 h was directly related to the relative
ipid volume and inversely related to the relative
brous volume. These observations are consistent
ith those reported in the present study.
The authors have investigated an important issue
hat is very relevant to daily interventional cardiol-
gy practice. In contrast to previous studies that
elied on surrogate markers, they directly assessed
yonecrosis to evaluate implications of plaque
omponents on periprocedural complications. The
uthors are appropriately cautious in the interpre-
ation of these observations as being hypothesis-
enerating and calling for their verification in ade- cuately powered prospective evaluations. Nonetheless,
o place their observations into context, some meth-
dological issues with VH-IVUS technology merit
onsideration.
The development of VH-IVUS offers us the
ossibility of identifying vulnerable or rupture-
rone atherosclerotic plaques, the pathological sub-
trate underlying up to 75% of episodes of acute
oronary syndromes and the most common cause of
udden death, by providing detailed assessment of
laque composition in vivo. It has the potential to
rovide new insights into the pathophysiology of
oronary artery disease and may allow for better
reatment stratification. However, before endorsing
H-IVUS, improvements in the existing technol-
gy that can better distinguish plaque morphology
re needed. For example, the spatial resolution of
H-IVUS (100 to 200 m) is far below that
eeded to detect vulnerable plaque characterized by
necrotic core with an overlying fibrous cap of
65 m thickness, the so-called thin-cap fibro-
theroma. These improvements in technology
ight also overcome its current limitations in dis-
inguishing necrotic core from calcification and in
order detection, thereby avoiding spurious conclu-
ions about culprit plaque composition. Currently,
ptical coherence tomography yields a higher spa-
ial resolution (10 to 20 m), and offers the poten-
ial to provide more accurate information on coro-
ary plaques. However, this technology is limited
y its inability to image through blood and lack of
enetration of deeper regions of plaque, thus ren-
ering it unwieldy and curtailing its widespread use
s a diagnostic tool. Although VH-IVUS technol-
gy has been validated in human coronary arteries
n ex vivo and in vivo studies with reasonably good
redictive accuracies, the virtual histological defini-
ion of vulnerable plaque awaits validation against
istopathological features. Furthermore, studies
omparing VH-IVUS with noninvasive imaging
ools such as multislice computed tomography and
ardiac magnetic resonance are required to evaluate
he optimal performance of these technologies in
laque characterization.
In addition to the limitations stated by the
uthors, other limitations of the current study need
o be acknowledged.
First, a previous study reported a strong positive
orrelation between necrotic core and dense calcium
olumes (8). Thus, it is unclear whether calcium is
mplicated in distal embolization and myonecrosis.
Second, tissue characterization by VH-IVUS is
urrently unable to distinguish intralesion throm-
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471us, a key contributor to distal embolization, from
ipid-rich components of the atherosclerotic plaque,
hereby confounding plaque assessment.
Third, the bulk of the friable material near to the
umen may be disrupted with the simple passage of
he IVUS catheter (Dotter effect). Therefore, tissue
haracterization will only be able to analyze the
esidual material left on the vessel wall. Given this,
t is extremely difficult to distinguish the effects of
he interventional procedure from the IVUS proce-
ure that preceded it on post-procedural biomarker
alues.
Fourth, although statistically significant, the cor-
elation between the necrotic core fraction (r 
.31, p  0.005) and fibro-fatty fraction (r 
0.27, p 0.015) at the minimum lumen site with
ost-PCI cTnI was rather modest.
Fifth, it is not clear which patient-related, lesion-
elated, and procedure-related variables were en-
ered into the univariable and multivariable models.
n addition, multiple regression models are unable
o account for unobserved covariates that may be
onfounded with troponin. Furthermore, even
hough the area under the receiver-operator char-
cteristic curve for absolute necrotic core area at the
inimum lumen site predicting post-PCI MI was
eported to be 0.914, indicating a high discriminant
alue, the incremental value of necrotic core area
ver patient-related, lesion-related, and procedure-
elated variables in predicting post-PCI biomarker
levation was not provided. Thus, it is unclear what
dditional relevant information, independent of
hese variables, can be gained from routine tissue
haracterization by VH-IVUS pre-PCI.
Sixth, although the authors used the universal
I definition criterion of 3 the upper limit of
ormal (99th percentile) as PCI-related MI (type
a), it is important to emphasize the arbitrary
ature of this criterion (3). Nonetheless, using
his arbitrary cutoff, post-PCI MI occurred fre-
uently (nearly 50%). Although the magnitude of
he increase in cTnI is not clear, the frequency of
I seems to be relatively high considering the
table patient presentation and nonurgent nature
f PCI. The impact of these biomarker elevations
n informed consent process, patient manage-
ent, length of stay, and so forth, is also not
lear. A recent report from the Mayo Clinic (4)
ndicated that extending hospitalization in these Eatients solely on the merits of a minor elevation
n cardiac troponin T, in the absence of a
ignificant procedural complication or clinical
ndications, is unlikely to be beneficial.
Seventh, the association between post-PCI
iomarker elevation and in-hospital and long-
erm adverse clinical outcomes was not provided
n this study. Thus, the clinical relevance of these
iomarker elevations remains unclear in the cur-
ent setting. Even if the prognostic implications
f post-PCI biomarker elevation were clearly well
stablished, its impact on clinical practice would
e predicated on the ability to modify post-PCI
iomarker elevation. Several investigations have
hown lack of benefit on infarct size, left ventric-
lar function and remodeling, or clinical outcome
ith distal protection devices in patients with
cute coronary syndromes. It is possible that
istal protection devices could be of potential
linical benefit in carefully selected patients in
hom high-risk plaques are identified by VH-
VUS. Similarly, selected high-risk patients
ight potentially benefit from more aggressive
ntithrombotic strategies, including higher doses
f clopidogrel or glycoprotein IIb/IIIa inhibitors
r newer agents such as prasugrel, although
urther studies are warranted to substantiate this
ypothesis.
Notwithstanding these limitations, the informa-
ion provided by the study of Hong et al. (7)
oupled with previous reports supports the rationale
ehind the hypothesis of using tissue characteriza-
ion to identify patients at higher risk of distal
mbolization and myonecrosis after stenting. These
bservations need to be validated prospectively in
arger cohorts of patients before routine use of
H-IVUS technology in clinical practice can be
ustified. Biomarker elevations in the setting of PCI
ndeed are messages from the heart. Someday we
ill more firmly link these messages with the
nderlying spectrum of plaque morphology—The
ainbow Connection. The current study is an im-
ortant step in that direction.
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